Evidence map›Paper›PMID 41528502›Full record

ReviewRheumatology international2026

Tofacitinib treatment in a girl with localized scleroderma of the head and face: a case-based review.

Agnieszka Gazda, Iryna Naishtetik, Hanna Grabowska, Anna Wolszczak, Małgorzata Gil, Beata Kołodziejczyk, Olga Krasowicz-Towalska, Piotr Gietka

Abstract readCase ReportsReview
PubMed Publisher
In one paragraph

Review in Rheumatology international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Agnieszka GazdaDepartment of Pediatric Rheumatology, Rheumatology and Rehabilitation, National Institute of Geriatrics, Warsaw, Poland.ORCID http://orcid.org/0000-0002-3771-9356
Iryna NaishtetikDepartment of Biological Treatment, Rheumatology and Rehabilitation, National Institute of Geriatrics, Warsaw, Poland. i.nayshtetik@gmail.com.ORCID http://orcid.org/0000-0002-8293-7993
Hanna GrabowskaMedical Departament Collegium Medicum, Cardinal Stefan Wyszynski University, Warsaw, Poland.ORCID http://orcid.org/0009-0002-0135-1315
Anna WolszczakMedical Departament Collegium Medicum, Cardinal Stefan Wyszynski University, Warsaw, Poland.ORCID http://orcid.org/0009-0006-7348-1185
Małgorzata GilMedical Departament Collegium Medicum, Cardinal Stefan Wyszynski University, Warsaw, Poland.ORCID http://orcid.org/0009-0002-7888-8874
Beata KołodziejczykMedical Departament Collegium Medicum, Cardinal Stefan Wyszynski University, Warsaw, Poland.ORCID http://orcid.org/0000-0001-9718-0543
Olga Krasowicz-TowalskaDepartment of Pediatric Rheumatology, Rheumatology and Rehabilitation, National Institute of Geriatrics, Warsaw, Poland.ORCID http://orcid.org/0009-0009-6853-8564
Piotr GietkaDepartment of Pediatric Rheumatology, Rheumatology and Rehabilitation, National Institute of Geriatrics, Warsaw, Poland.ORCID http://orcid.org/0000-0002-2413-0083

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

En coup de sabre scleroderma (ECDS) and progressive hemifacial atrophy (PHA) are classified as forms of linear scleroderma of the head and face, a subset of juvenile localized scleroderma (JLoS). In ECDS, sclerotic lesions primarily localize to the forehead and frontoparietal scalp, typically unilaterally. PHA involves the atrophy of facial soft tissues and adjacent cartilage-bone structures on one side, leading to significant deformities. Both forms may involve the eye and central nervous system (CNS), potentially presenting with hemiplegia in PHA. These conditions can coexist and require immediate, intensive immunosuppressive treatment to halt the disease process. This case report describes the clinical management of a female patient diagnosed with ECDS and PHA at age 5, alongside limited superficial morphea lesions on the face. The patient was treated with high-dose glucocorticosteroids, methotrexate (MTX), cyclosporine A (CsA), and intravenous immunoglobulin (IVIG), achieving transient stabilization. No ophthalmological or neurological symptoms were observed, and brain magnetic resonance imaging (MRI) remained normal. Disease extent was monitored via clinical examination, the Localized Scleroderma Cutaneous Assessment Tool (LoSCAT), and facial MRI assessing skin and subcutaneous tissue thickness. Due to disease progression, tofacitinib was initiated. Over a one-year observation period, stabilization of lesions was achieved with no recorded complications.

Indexed as

Facial HemiatrophyPiperidinesProtein Kinase InhibitorsPyrimidinesScleroderma, LocalizedChild, PreschoolCyclosporineFemaleHumansImmunosuppressive AgentsMethotrexateTreatment OutcomeCyclosporineImmunosuppressive AgentsMethotrexatePiperidinesProtein Kinase InhibitorsPyrimidinestofacitinibConnective tissue diseasesFacial hemiatrophyParry-Romberg syndromeScleroderma, localized

Identifiers

PMID41528502

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.